ESMO 2025 preview – Astra and Daiichi keep abreast of Gilead
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
A milestone for Tmalin
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
US shutdown freezes new drug applications
Key FDA decisions are expected to face delays.
Takeda’s cancer prospects dim further
After trimming its cell therapy pipeline last year, the group is now out entirely.
Astra's clash of the T-cell engager Titans
The Titan CD8-guiding technology seems to have spawned a new variant.
